Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Applied Therapeutics, Inc. due to allegations of securities law violations related to misleading statements and undisclosed adverse facts concerning the company's clinical trials and regulatory submissions [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in Applied Therapeutics to discuss their legal options [1]. - A federal securities class action has been filed against Applied Therapeutics, with a deadline of February 18, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false statements and failed to disclose significant issues regarding the Phase III INSPIRE trial, which misled investors [4]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the New Drug Application for govorestat, Applied Therapeutics' stock price fell by $1.64 per share, or 16.06%, closing at $8.57 on November 27, 2024 [5]. - After the FDA issued a Warning Letter indicating that the company was aware of significant issues with the govorestat NDA, the stock price dropped by $0.31 per share, or 18.34%, closing at $1.38 on December 4, 2024 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Applied Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on February 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by February 18, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding their clinical trial protocols, which created a false impression of compliance with good clinical practices [5]. - It is claimed that the company's failure to adhere to proper trial protocols posed a severe risk of FDA rejection of trial data in a New Drug Application [5].

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=127301&from=3 CLASS P ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Applied Therapeutics, Inc. regarding a class action lawsuit due to significant stock price declines following negative FDA communications about the company's lead drug candidate, govorestat [1][2]. Group 1: Company Overview - Applied Therapeutics, Inc. is facing legal action after its stock price fell dramatically due to a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [2]. - The stock price dropped from $10.21 per share on November 26, 2024, to $8.57 on November 27, 2024, and further declined to $2.03 on November 29, 2024, and $1.75 on December 2, 2024, marking a total decline of over 80% [2]. Group 2: Legal Proceedings - The class period for the lawsuit is defined as January 3, 2024, to December 2, 2024, with a deadline for shareholders to register as lead plaintiffs set for February 18, 2025 [3]. - Following the disclosure of a "warning letter" from the FDA on December 2, 2024, regarding clinical trial issues, the stock price continued to decline, reaching $1.69 on December 3, 2024, and further to $1.29 on December 5, 2024 [2]. Group 3: Shareholder Actions - Shareholders are encouraged to register for the class action lawsuit to monitor the case's progress, with no cost or obligation to participate [3]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by the company [4].

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Applied Therapeu ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=126267&from=4CLASS PERIOD: Ja ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Applied Therapeutics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ ...

NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...